What You Should Know:
– Johnson & Johnson’s Janssen Pharmaceuticals company announced it is working with Alveo Technologies, an innovative diagnostic testing company, to help bring its COVID-19 rapid at-home self-testing platform for viral infectious diseases to market.
– Johnson & Johnson’s Janssen Pharmaceuticals company will work with and fund Alveo to accelerate research and development of be.well .
– Alveo will use a phased approach and first seek Emergency Use Authorization (EUA) for a SARS-CoV-2 assay, followed by a multiplex version for home use.
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc., (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance Alveo’s be.well™ platform of analyzers, nasal swabs and cartridges for the detection of viral infectious diseases, including Respiratory Syncytial Virus (RSV) and potentially SARS-CoV-2. Alveo will use a phased approach to first gain Emergency Use Authorization (EUA) for a SARS-CoV-2 assay, followed by a multiplex assay for home use.
The company’s be.well™ testing system gives individuals
access to cutting-edge molecular testing and cloud-based data analytics
for rapid diagnosis and management of infectious diseases. With an initial
focus on acute respiratory infections, including COVID-19,
Influenza A/B and RSV, Alveo’s agile and dynamic
diagnostic platform can be adapted to detect a wide range of diseases that
threaten public health. Alveo will receive financial support
as well as technical and regulatory counsel from Janssen relating to the
regulatory submission of the be.well™ platform, which is designed to diagnose a
range of viral infections.
“With be.well™, we are talking about an entirely new approach to detect and
help manage infectious diseases in individuals and populations,” said Ron
Chiarello, PhD, Founder, CEO and Chairman of the Board of Alveo. “With a
low-cost, easy-to-use device/app combination, we expect to have real-time
diagnostic data to track and respond to disease outbreaks at a speed and scale
that we could not have come close to previously. Janssen’s technical and
regulatory support will help advance our platform, which we hope will empower
people for the first time at home with on-demand infectious disease detection
that may enable receiving treatment at the earliest possible time – saving
countless lives and medical resources – and enabling global infectious disease surveillance
on a scale, and at a speed, never seen before.”
